Pertactin-Deficient Bordetella pertussis Rose After Acellular Vaccines

Pertactin-deficient Bordetella pertussis became much more common in several countries after acellular whooping cough vaccines were widely introduced. The pattern matters because pertactin is one of the bacterial antigens included in many acellular pertussis vaccines, and its disappearance from circulating strains looks like a real-world example of pathogen adaptation.

Acellular Vaccines and Pertactin

Here is the basic idea. Acellular pertussis vaccines do not use the whole bacterium. They use selected pieces of it, including proteins such as pertactin. If a strain loses pertactin but still spreads, it may face less immune pressure from vaccines that specifically target that protein. Researchers have reported this shift in places including the United States, Australia, Japan, and parts of Europe during the 2000s and 2010s.

The striking part is that this was not just a rare lab curiosity. In some settings, pertactin-deficient strains went from uncommon to dominant among sampled Bordetella pertussis isolates. That does not prove every step of the selection process with absolute certainty, but it does strongly suggest vaccine-related pressure helped favor strains that no longer make the pertactin antigen.

Vaccine Pressure and Strain Shift

That finding can sound bigger or scarier than it is, so the balance matters. The rise of pertactin-deficient strains did not mean vaccines suddenly stopped working. Acellular pertussis vaccines target multiple antigens, not just pertactin, and they still reduce the risk of severe disease. At the same time, scientists have been clear that pathogen populations can shift under immune pressure, and this may be one reason pertussis control has remained challenging even in highly vaccinated countries.

The consequence is practical, not dramatic. When one vaccine-targeted antigen becomes less common in the wild, it tells researchers that surveillance has to track not only case counts, but also which bacterial traits are changing over time. It also strengthens the case for improving pertussis vaccines and updating strategy based on how the bacterium is evolving in actual populations, not in theory.

Pertussis Surveillance and Vaccine Strategy

So the concrete takeaway is this: in the years after acellular pertussis vaccines became standard in multiple countries, Bordetella pertussis strains missing pertactin rose noticeably. That shift is one of the clearest examples of an important public-health reality: bacteria can adapt to selective pressure, while vaccines can still remain useful at reducing serious illness.

Did You Know?

Source